135 related articles for article (PubMed ID: 33118484)
1. The putative binding site and SAR rationalization of small molecules against glucagon-like peptide-1 receptor using homology model and crystal structures: a comparative study.
Thamaraiselvan V; Velayutham R
J Biomol Struct Dyn; 2022 Mar; 40(5):2038-2052. PubMed ID: 33118484
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
Thompson A; Stephens JW; Bain SC; Kanamarlapudi V
PLoS One; 2016; 11(4):e0154229. PubMed ID: 27100083
[TBL] [Abstract][Full Text] [Related]
3. A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.
Jun LS; Showalter AD; Ali N; Dai F; Ma W; Coskun T; Ficorilli JV; Wheeler MB; Michael MD; Sloop KW
PLoS One; 2014; 9(4):e93746. PubMed ID: 24695667
[TBL] [Abstract][Full Text] [Related]
4. Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R).
Koole C; Reynolds CA; Mobarec JC; Hick C; Sexton PM; Sakmar TP
J Biol Chem; 2017 Apr; 292(17):7131-7144. PubMed ID: 28283573
[TBL] [Abstract][Full Text] [Related]
5. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.
Redij T; Ma J; Li Z; Hua X; Li Z
J Comput Aided Mol Des; 2019 Nov; 33(11):973-981. PubMed ID: 31758355
[TBL] [Abstract][Full Text] [Related]
7. Investigation of ECD conformational transition mechanism of GLP-1R by molecular dynamics simulations and Markov state model.
Zhang J; Bai Q; Pérez-Sánchez H; Shang S; An X; Yao X
Phys Chem Chem Phys; 2019 Apr; 21(16):8470-8481. PubMed ID: 30957116
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
[TBL] [Abstract][Full Text] [Related]
9. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway.
Thompson A; Kanamarlapudi V
Biochem Pharmacol; 2015 Jan; 93(1):72-84. PubMed ID: 25449603
[TBL] [Abstract][Full Text] [Related]
10. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Cheong YH; Kim MK; Son MH; Kaang BK
Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
[TBL] [Abstract][Full Text] [Related]
11. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Yang D; de Graaf C; Yang L; Song G; Dai A; Cai X; Feng Y; Reedtz-Runge S; Hanson MA; Yang H; Jiang H; Stevens RC; Wang MW
J Biol Chem; 2016 Jun; 291(25):12991-3004. PubMed ID: 27059958
[TBL] [Abstract][Full Text] [Related]
12. Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists.
Girdhar K; Dehury B; Kumar Singh M; Daniel VP; Choubey A; Dogra S; Kumar S; Mondal P
J Biomol Struct Dyn; 2019 Sep; 37(15):3976-3986. PubMed ID: 30296922
[TBL] [Abstract][Full Text] [Related]
13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
15. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor action in the vasculature.
Almutairi M; Al Batran R; Ussher JR
Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
[TBL] [Abstract][Full Text] [Related]
17. The putative signal peptide of glucagon-like peptide-1 receptor is not required for receptor synthesis but promotes receptor expression.
Ge Y; Yang D; Dai A; Zhou C; Zhu Y; Wang MW
Biosci Rep; 2014 Nov; 34(6):e00152. PubMed ID: 25330813
[TBL] [Abstract][Full Text] [Related]
18. The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties.
Irwin DM; Satkunarajah M; Wen Y; Brubaker PL; Pederson RA; Wheeler MB
Proc Natl Acad Sci U S A; 1997 Jul; 94(15):7915-20. PubMed ID: 9223287
[TBL] [Abstract][Full Text] [Related]
19. Structural Modeling and in Silico Screening of Potential Small-Molecule Allosteric Agonists of a Glucagon-like Peptide 1 Receptor.
Redij T; Chaudhari R; Li Z; Hua X; Li Z
ACS Omega; 2019 Jan; 4(1):961-970. PubMed ID: 31459371
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
